Vera Therapeutics (VERA)
NASDAQ:VERA
Want to see VERA full AI Analyst Report?
Top Page
Vera Therapeutics
(NASDAQ:VERA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$35.00
▼(-17.26% Downside)
Action:Reiterated
Date:05/10/26
The score is driven primarily by weak financial performance (no revenue, accelerating losses, and rising cash burn), partially offset by a relatively low-leverage balance sheet with meaningful equity. Technicals add modest pressure given bearish momentum and price below key moving averages, while valuation remains constrained by negative earnings and no dividend.
Positive Factors
Low leverage and sizable equity
The company’s low leverage and roughly $500M of equity provide durable financing flexibility to fund clinical programs and absorb setbacks. This balance sheet strength reduces near-term refinancing risk and supports partnerships or milestone-driven deals that can sustain development timelines.
Negative Factors
Pre-revenue with rapidly widening losses
Being pre-revenue means the company’s valuation and sustainability hinge entirely on clinical success. Rapidly expanding losses increase the magnitude of required capital and the risk that programs underperform, which can materially impair shareholder value absent successful development or partnership outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and sizable equity
The company’s low leverage and roughly $500M of equity provide durable financing flexibility to fund clinical programs and absorb setbacks. This balance sheet strength reduces near-term refinancing risk and supports partnerships or milestone-driven deals that can sustain development timelines.
Read all positive factors
Vera Therapeutics (VERA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.68B
Dividend YieldN/A
Average Volume (3M)1.31M
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth-85.06%
CountryUS
Employees152
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume1,422,343
30 Day Avg. Volume1,307,883
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.57K
Enterprise Value/Ebitda-7.28
Forecast
1Y Price Target
$77.67Price Target Upside83.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.89
Revenue Forecast (FY)$39.06M
Vera Therapeutics Business Overview & Revenue Model
Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein ...
How the Company Makes Money
As a clinical-stage biotechnology company, Vera Therapeutics has not commercialized a product and has historically not generated product sales revenue; accordingly, recurring operating revenue from marketed drugs is null. The company’s funding to ...
Vera Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.00K | 0.00 | 0.00 | 0.00 | 846.00K | 0.00 |
| EBITDA | -362.77M | -291.62M | -144.42M | -92.18M | -88.91M | -32.41M |
| Net Income | -368.95M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
Balance Sheet | ||||||
| Total Assets | 621.74M | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M |
| Cash, Cash Equivalents and Short-Term Investments | 596.76M | 714.59M | 640.85M | 160.72M | 114.65M | 79.67M |
| Total Debt | 75.03M | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M |
| Total Liabilities | 122.04M | 130.21M | 78.53M | 73.86M | 54.53M | 14.16M |
| Stockholders Equity | 499.70M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
Cash Flow | ||||||
| Free Cash Flow | -293.81M | -241.73M | -135.65M | -92.24M | -67.66M | -23.71M |
| Operating Cash Flow | -293.20M | -241.10M | -134.68M | -92.18M | -67.60M | -23.71M |
| Investing Cash Flow | 41.15M | 194.29M | -425.03M | -39.43M | -70.55M | -4.20M |
| Financing Cash Flow | 311.31M | 308.90M | 606.67M | 133.54M | 101.93M | 53.88M |
Vera Therapeutics Technical Analysis
Positive
42.30
Price Trends
41.23
Positive
43.31
Negative
34.31
Positive
Market Momentum
0.59
Negative
53.00
Neutral
45.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Positive. The current price of 42.3 is above the 20-day moving average (MA) of 41.14, above the 50-day MA of 41.23, and above the 200-day MA of 34.31, indicating a bullish trend. The MACD of 0.59 indicates Negative momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 45.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERA.
Vera Therapeutics Risk Analysis
Vera Therapeutics disclosed 86 risk factors in its most recent earnings report. Vera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $3.56B | -17.21 | -32.55% | ― | ― | -7.28% | |
52 Neutral | $1.73B | -4.76 | -60.70% | ― | 23382.78% | 7.01% | |
52 Neutral | $1.99B | -10.01 | -67.38% | ― | ― | -5.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $847.07M | -8.94 | -11.55% | ― | 47.10% | -35.51% | |
45 Neutral | $2.68B | -5.94 | -74.86% | ― | ― | -85.06% | |
44 Neutral | $1.32B | -2.39 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
VERA
Vera Therapeutics
37.32
16.31
77.63%
VRDN
Viridian Therapeutics
16.82
4.00
31.20%
PHVS
Pharvaris
30.40
13.71
82.14%
EWTX
Edgewise Therapeutics
33.09
18.30
123.73%
JANX
Janux Therapeutics Inc
13.89
-10.28
-42.53%
BHVN
Biohaven Ltd.
8.76
-6.99
-44.38%
Vera Therapeutics Corporate Events
Executive/Board Changes
Vera Therapeutics Adds Christopher Hite to Board
Positive
Mar 9, 2026
On March 5, 2026, Vera Therapeutics, Inc. appointed Christopher Hite to its board of directors as a Class III director, with his initial term running through the 2027 annual meeting of stockholders. As part of his compensation, Hite received a non...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.